Antimalarial activity of a riboflavin analog against Plasmodium vinckei in vivo and Plasmodium falciparum in vitro.
The riboflavin analog 10-(4'-chlorophenyl)-3-methylflavin was found to have significant activity against Plasmodium vinckei vinckei when administered orally and parenterally; it was active against P. falciparum in culture. It inhibited mouse erythrocyte glutathione reductase in a dose-dependent manner. When administered orally, 5-deazariboflavin was not active in vivo although it has been shown to have activity against P. falciparum in vitro.
Cowden
W B
WB
Department of Experimental Pathology, John Curtin School of Medical Research, Canberra, Australia.
Butcher
G A
GA
Hunt
N H
NH
Clark
I A
IA
Yoneda
F
F
D000284:Administration, Oral; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D005260:Female; D007274:Injections, Intraperitoneal; D008288:Malaria / Q000188:drug therapy*; D051379:Mice; D008808:Mice, Inbred CBA; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors; D010961:Plasmodium / Q000187:drug effects*; D012256:Riboflavin / Q000031:analogs & derivatives*
D000962:Antimalarials; D009247:NADH, NADPH Oxidoreductases; C019976:Cystine reductase; D012256:Riboflavin